Literature DB >> 2128443

Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis.

B Fantin1, C Carbon.   

Abstract

The penicillin-aminoglycoside combination is recommended for the treatment of systemic enterococcal infections. However, the optimal dosing regimen of the aminoglycoside remains to be elucidated. We evaluated the efficacy of penicillin, alone or in combination with various dosing regimens of netilmicin, for the treatment of experimental left-sided Enterococcus faecalis endocarditis in rabbits. Animals were injected intramuscularly for 4 days with penicillin alone or in combination with netilmicin in one of the following regimens: netilmicin at a low dose (2 mg/kg of body weight every 8 h), netilmicin at a high dose (4 mg/kg every 8 h), or netilmicin at a single daily high dose (12 mg/kg every 24 h). MICs and MBCs were 3.1 and 6.2 micrograms/ml and 8 and 8 micrograms/ml for penicillin and netilmicin, respectively. A netilmicin concentration of 4 micrograms/ml was the lowest concentration that achieved synergism with penicillin, as shown by the kill-curve method. Mean peak levels of netilmicin in serum were 5.6 (netilmicin at 2 mg/kg), 9.8 (netilmicin at 4 mg/kg), and 20.6 (netilmicin at 12 mg/kg) micrograms/ml. Mean penicillin levels in serum were constantly above the MIC. Penicillin plus netilmicin at a high dose given three times daily was more effective (P less than 0.05) than any other regimen in reducing bacterial titers in vegetations and was the only treatment that induced a significant bactericidal activity in rabbit serum during the trough. We concluded that divided doses of aminoglycoside are more effective than the same total dose given once daily in combination with penicillin. Our data suggest that prolonged levels of aminoglycoside in serum might be important to exhibit the greatest in vivo efficacy of the combination against E. faecalis. They also indicate that use of a reduced total daily dose of aminoglycoside or an increase in the interval between each dose might reduce the efficacy of therapy in animals with this type of infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2128443      PMCID: PMC172066          DOI: 10.1128/AAC.34.12.2387

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Influence of gentamicin dose size on the efficacies of combinations of gentamicin and penicillin in experimental streptomycin-resistant enterococcal endocarditis.

Authors:  A J Wright; W R Wilson; J Y Matsumoto; J A Washington; J E Geraci
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

2.  Penicillin and netilmicin in treatment of experimental enterococcal endocarditis.

Authors:  J Carrizosa; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

3.  Penicillin-netilmicin synergism against Streptococcus faecalis.

Authors:  O M Korzeniowski; C Wennersten; R C Moellering; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

4.  Gentamicin, netilmicin, dibekacin, and amikacin nephrotoxicity and its relationship to tubular reabsorption in rabbits.

Authors:  N Brion; J Barge; I Godefroy; F Dromer; C Dubois; A Contrepois; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

5.  The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess.

Authors:  C A Wood; D R Norton; S J Kohlhepp; P W Kohnen; G A Porter; D C Houghton; R E Brummett; W M Bennett; D N Gilbert
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

6.  Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans.

Authors:  A Contrepois; N Brion; J J Garaud; F Faurisson; F Delatour; J C Levy; J C Deybach; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

7.  Treatment of streptomycin-susceptible enterococcal experimental endocarditis with combinations of penicillin and low- or high-dose streptomycin.

Authors:  N K Henry; W R Wilson; J E Geraci
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

8.  Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin.

Authors:  S H Powell; W L Thompson; M A Luthe; R C Stern; D A Grossniklaus; D D Bloxham; D L Groden; M R Jacobs; A O DiScenna; H A Cash; J D Klinger
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

9.  Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia.

Authors:  J E Kapusnik; C J Hackbarth; H F Chambers; T Carpenter; M A Sande
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

10.  In vivo postantibiotic effect in a thigh infection in neutropenic mice.

Authors:  B Vogelman; S Gudmundsson; J Turnidge; J Leggett; W A Craig
Journal:  J Infect Dis       Date:  1988-02       Impact factor: 5.226

View more
  18 in total

Review 1.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 2.  Epidemiology and antibiotic treatment of infective endocarditis: an update.

Authors:  Bruno Hoen
Journal:  Heart       Date:  2006-11       Impact factor: 5.994

3.  Once-daily dosing of aminoglycosides.

Authors:  J Blaser; C König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-12       Impact factor: 3.267

4.  Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis.

Authors:  P López; J Gavaldà; M T Martin; B Almirante; X Gomis; C Azuaje; N Borrell; L Pou; V Falcó; C Pigrau; A Pahissa
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

5.  Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  C Darras-Joly; J P Bédos; C Sauve; P Moine; E Vallée; C Carbon; E Azoulay-Dupuis
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

6.  Once-versus thrice-daily netilmicin combined with amoxicillin, penicillin, or vancomycin against Enterococcus faecalis in a pharmacodynamic in vitro model.

Authors:  S Schwank; J Blaser
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

7.  Effect of gentamicin dosing interval on therapy of viridans streptococcal experimental endocarditis with gentamicin plus penicillin.

Authors:  J Gavaldà; A Pahissa; B Almirante; M Laguarda; E Crespo; L Pou; F Fernández
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 8.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Simulated human serum profiles of one daily dose of ceftriaxone plus netilmicin in treatment of experimental streptococcal endocarditis.

Authors:  M Blatter; U Fluckiger; J Entenza; M P Glauser; P Francioli
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

10.  Synergistic activity of ceftriaxone combined with netilmicin administered once daily for treatment of experimental streptococcal endocarditis.

Authors:  P B Francioli; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.